A National, Multicenter, Open Label, Randomized Phase III study for Induction therapy with BORTEZOMIB/ LENALIDOMIDE/ DEXAMETHASONE (VRD-GEM) followed by High-dose Chemotherapy with MELPHALAN-200 (MEL-200) vs. BUSULFAN/MELPHALAN (BUMEL) and Consolidation t

Rate of complete remission (CR) with negative immunofixation after each stage of treatment (induction and consolidation autotransplantation). Evaluation of minimal residual disease (MRD) in patients with negative immunofixation RC-after each stage of treatment (induction and consolidation autotransplantation). Overall survival (OS) after PBSCT with BuMel vs. MEL-200. To evaluate the safety and tolerability of induction and consolidation treatment.